FindTrial
Sign In

A prospective, radomized, double-blind, parallel-controlled clinicl trial to evaluated the effectiveness of recombinant human erythropoietin in prevetion of post-operative acute kidney injury

The effectiveness of recombinant human erythropoietin in prevetion of post-operative acute kidney injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15005979
Enrollment
Unknown
Registered
2014-12-09
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury

Interventions

intervention group:preoperative given rhEPO
Control gro:preoperative given placebo

Sponsors

Peking Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Chinese men or women aged 18 years to 70 years; 2. Scheduled for vascular operation, or cardiac surgery; 3. Have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Known allergy or hypersensitivity to EPO; 2. Uncontrolled hypertension; 3. Obvious polycythemia; 4. Recent history of thromboembolism; 5. Researchers consider inappropriate to participate the trial.

Design outcomes

Primary

MeasureTime frame
serum creatinine;—

Secondary

MeasureTime frame
urine NGAL;—

Countries

China

Contacts

Public ContactLi Xuemei
lixmpumch@126.com+86 10 69154056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026